首页|期刊导航|Oncology Research|Disitamab Vedotin in HER2-Positive and HER2-Low Breast Cancer:A Multicenter Retrospective Analysis
Oncology Research2025,Vol.33Issue(9):P.2529-2547,19.DOI:10.32604/or.2025.065029
Disitamab Vedotin in HER2-Positive and HER2-Low Breast Cancer:A Multicenter Retrospective Analysis
摘要
关键词
Disitamab vedotin/antibody-drug conjugates/real-world study/breast cancer/HER2-low/HER2-RC48/ADC分类
医药卫生引用本文复制引用
Xizhou Zhang,Zetao Zhang,Jianguang Lin,Jiarong Yi,Xuxiazi Zou,Jikun Feng,Guangsheng Huang,Bingfeng Chen,Junxi Long,Fengjia Wu,Feng Ye,Haoming Wu..Disitamab Vedotin in HER2-Positive and HER2-Low Breast Cancer:A Multicenter Retrospective Analysis[J].Oncology Research,2025,33(9):P.2529-2547,19.基金项目
funded by the medical and health category of the Science and Technology Project of Shantou(No.230509116495542,Wu Haoming) (No.230509116495542,Wu Haoming)
National Natural Science Foundation of China(NSFC)Cultivation Project of the Cancer Hospital of Shantou University Medical College(No.2024GP002,Wu Haoming) (NSFC)
National Natural Science Foundation of China(82203130,Ye Feng). (82203130,Ye Feng)